-
公开(公告)号：US10220084B2
公开(公告)日：2019-03-05
申请号：US14969882
申请日：2015-12-15
Applicant: The Texas A&M University System
Inventor： Thomas A. Ficht , Allison Ficht , Renee Tsolis , Leslie Garry Adams
IPC: A61K39/09 , A61K39/02 , G01N33/569 , A61K39/00
Abstract: Methods and compositions for the treatment of Brucella induced diseases and disorders are disclosed herein. In preferred embodiments, the invention relates to vaccines. In additional embodiments, the invention relates to formulations capable of releasing said vaccines at a controlled rate of release in vivo. In further embodiments, the invention relates to modified strains of the bacteria Brucella melitensis and Brucella abortus. In still further embodiments, the invention relates to compositions that do not induce clinical symptoms or splenomegaly in a subject receiving said compositions.
-
公开(公告)号：US09802991B2
公开(公告)日：2017-10-31
申请号：US15073809
申请日：2016-03-18
Applicant: THE TEXAS A&M UNIVERSITY SYSTEM
Inventor： Allison Ficht , Theresa Good , Kenneth Carson , Sungmun Lee
CPC classification number: C07K14/44 , A61K38/00 , C07K14/4702 , C07K14/4711 , C07K2319/35
Abstract: The present inventions are compositions and methods of using at least a portion of an isolated and purified α-crystallin polypeptide that includes one or more β-pleated sheets and that prevents neurotoxicity and amyloidogenesis.
-
3.发明申请Controlled Release Vaccines and Methods of Treating Brucella Diseases and Disorders 审中-公开控制释放疫苗和治疗布鲁杆菌疾病和疾病的方法公开(公告)号：US20160095913A1
公开(公告)日：2016-04-07
申请号：US14969882
申请日：2015-12-15
Applicant: The Texas A&M University System
Inventor： Thomas A. Ficht , Allison Ficht , Renee Tsolis , Leslie Garry Adams
IPC: A61K39/02 , G01N33/569
CPC classification number: A61K39/098 , A61K2039/522 , A61K2039/54 , A61K2039/541 , A61K2039/622 , G01N33/56911 , G01N2333/23 , G01N2469/20 , G01N2800/52
Abstract: Methods and compositions for the treatment of Brucella induced diseases and disorders are disclosed herein. In preferred embodiments, the invention relates to vaccines. In additional embodiments, the invention relates to formulations capable of releasing said vaccines at a controlled rate of release in vivo. In further embodiments, the invention relates to modified strains of the bacteria Brucella melitensis and Brucella abortus. In still further embodiments, the invention relates to compositions that do not induce clinical symptoms or splenomegaly in a subject receiving said compositions.
Abstract translation: 本文公开了用于治疗布鲁杆菌诱导的疾病和病症的方法和组合物。 在优选的实施方案中，本发明涉及疫苗。 在另外的实施方案中，本发明涉及能够以受控的体内释放速率释放所述疫苗的制剂。 在进一步的实施方案中，本发明涉及细菌布鲁氏菌（Brucella melitensis）和流产布鲁杆菌（Brucella abortus）的修饰菌株。 在另外的实施方案中，本发明涉及在接受所述组合物的受试者中不诱导临床症状或脾肿大的组合物。
-
公开(公告)号：US11975060B2
公开(公告)日：2024-05-07
申请号：US17151488
申请日：2021-01-18
Applicant: The Texas A&M University System
Inventor： Thomas A. Ficht , Allison Ficht , Renee Tsolis , Leslie Garry Adams , Angela M. Arenas-Gamboa
IPC: A61K39/00 , A61K39/02 , G01N33/569
CPC classification number: A61K39/098 , G01N33/56911 , A61K2039/522 , A61K2039/54 , A61K2039/541 , A61K2039/622 , G01N2333/23 , G01N2469/20 , G01N2800/52
Abstract: Methods and compositions for the treatment of Brucella induced diseases and disorders are disclosed herein. In preferred embodiments, the invention relates to vaccines. In additional embodiments, the invention relates to formulations capable of releasing said vaccines at a controlled rate of release in vivo. In further embodiments, the invention relates to modified strains of the bacteria Brucella melitensis and Brucella abortus. In still further embodiments, the invention relates to compositions that do not induce clinical symptoms or splenomegaly in a subject receiving said compositions.
-
公开(公告)号：US10940193B2
公开(公告)日：2021-03-09
申请号：US16251757
申请日：2019-01-18
Applicant: The Texas A&M University System
Inventor： Thomas A. Ficht , Allison Ficht , Renee Tsolis , Leslie Garry Adams , Angela M. Arenas-Gamboa
IPC: A61K39/02 , G01N33/569 , A61K39/00
Abstract: Methods and compositions for the treatment of Brucella induced diseases and disorders are disclosed herein. In preferred embodiments, the invention relates to vaccines. In additional embodiments, the invention relates to formulations capable of releasing said vaccines at a controlled rate of release in vivo. In further embodiments, the invention relates to modified strains of the bacteria Brucella melitensis and Brucella abortus. In still further embodiments, the invention relates to compositions that do not induce clinical symptoms or splenomegaly in a subject receiving said compositions.
-
Patent Agency Ranking
公开(公告)号：US20230241195A1
公开(公告)日：2023-08-03
申请号：US18009095
申请日：2021-06-10
Applicant: THE TEXAS A&M UNIVERSITY SYSTEM
Inventor： Jamie B. Felix , Sankar P. Chaki , Walter E. Cook , Allison Ficht , Thomas A. Ficht
CPC classification number: A61K39/07 , A61K9/0053 , A61K9/5052 , A61K9/4866 , A61K2039/52
Abstract: Methods and compositions for the immunization of animals and humans using an oral immunization or vaccine that comprises B. anthracis Sterne strain 34F2 spores suspended in alginate and coated with a shell containing poly-L-lysine (PEL), a vitelline protein B (VpB), or both and an external coating of alginate in an amount sufficient to protect an animal or human from a lethal dose of anthrax.
-
公开(公告)号：US20210386848A1
公开(公告)日：2021-12-16
申请号：US17151488
申请日：2021-01-18
Applicant: The Texas A&M University System
Inventor： Thomas A. Ficht , Allison Ficht , Renee Tsolis , Leslie Garry Adams , Angela M. Arenas-Gamboa
IPC: A61K39/02 , G01N33/569
Abstract: Methods and compositions for the treatment of Brucella induced diseases and disorders are disclosed herein. In preferred embodiments, the invention relates to vaccines. In additional embodiments, the invention relates to formulations capable of releasing said vaccines at a controlled rate of release in vivo. In further embodiments, the invention relates to modified strains of the bacteria Brucella melitensis and Brucella abortus. In still further embodiments, the invention relates to compositions that do not induce clinical symptoms or splenomegaly in a subject receiving said compositions.
-
公开(公告)号：US20190142923A1
公开(公告)日：2019-05-16
申请号：US16251757
申请日：2019-01-18
Applicant: The Texas A&M University System
Inventor： Thomas A. Ficht , Allison Ficht , Renee Tsolis , Leslie Garry Adams , Angela M. Arenas-Gamboa
IPC: A61K39/02 , G01N33/569
Abstract: Methods and compositions for the treatment of Brucella induced diseases and disorders are disclosed herein. In preferred embodiments, the invention relates to vaccines. In additional embodiments, the invention relates to formulations capable of releasing said vaccines at a controlled rate of release in vivo. In further embodiments, the invention relates to modified strains of the bacteria Brucella melitensis and Brucella abortus. In still further embodiments, the invention relates to compositions that do not induce clinical symptoms or splenomegaly in a subject receiving said compositions.
-
公开(公告)号：US20140303088A1
公开(公告)日：2014-10-09
申请号：US14251709
申请日：2014-04-14
Applicant: The Texas A&M University System
Inventor： Allison Ficht , Theresa Good , Ken Carson , Sungmun Lee
IPC: C07K14/44
CPC classification number: C07K14/44 , A61K38/00 , C07K14/4702 , C07K14/4711 , C07K2319/35
Abstract: The present invention compositions and methods of using at least a portions of an isolated and purified α-crystallin polypeptide that includes one or more β-pleated sheets and that prevents neurotoxicity and amyloidogenesis.
Abstract translation: 本发明的组合物和使用至少一部分分离和纯化的α-晶状蛋白多肽的组合物和方法，所述α-晶状体蛋白多肽包含一个或多个复合片，并且可防止神经毒性和淀粉样变。
-
公开(公告)号：US20240307519A1
公开(公告)日：2024-09-19
申请号：US18576813
申请日：2022-07-07
Applicant: THE TEXAS A&M UNIVERSITY SYSTEM
Inventor： Jamie Suzanne Benn , Chase M. Nunez , Walter E. Cook , Allison Ficht , Thomas A. Ficht , Sankar P. Chaki
CPC classification number: A61K39/07 , C12N11/10 , A61K2039/542 , A61K2039/552 , A61K2039/55555 , A61K2039/575 , C12R2001/07
Abstract: Methods and compositions for the immunization of animals and humans using an immunization or vaccine that comprises B. anthracis Sterne strain 34F2 spores suspended in alginate in an amount sufficient to protect an animal or human from a lethal dose of anthrax.
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.023 seconds)
